Diagnosing dementia involves a combination of cognitive testing, medical history, physical examination, brain imaging, and blood work. There is no single test that confirms dementia. Instead, doctors piece together evidence from multiple sources to determine whether cognitive decline is significant enough to interfere with daily life, and then work to identify the specific type causing it.
The process typically begins with a primary care visit and can take weeks to months depending on how many specialists and tests are needed. Understanding each step can help you know what to expect, whether you’re concerned about yourself or a loved one.
What Doctors Are Actually Looking For
A dementia diagnosis rests on two key findings. First, a person must show meaningful decline in at least one area of thinking, such as memory, attention, language, reasoning, or spatial awareness. Second, that decline must be severe enough to affect everyday functioning. Someone who scores low on a memory test but still manages their medications, finances, and daily routine independently would not meet the threshold for dementia. They might instead receive a diagnosis of mild cognitive impairment, which sometimes progresses to dementia and sometimes doesn’t.
The latest diagnostic frameworks have shifted how Alzheimer’s disease specifically is defined. The 2024 criteria from the National Institute on Aging and the Alzheimer’s Association now define Alzheimer’s biologically, through measurable changes in the brain, rather than based solely on symptoms. This means the disease is understood as a continuum that begins with brain changes in people who have no symptoms at all and progresses through stages of increasing severity. In practice, this has opened the door to blood-based biomarker tests that can detect the disease earlier than ever before.
The Initial Office Visit
The diagnostic process usually starts with a detailed conversation. Your doctor will ask about the specific changes you or your family have noticed: forgetting recent conversations, getting lost in familiar places, struggling with word-finding, difficulty managing bills, or changes in personality and judgment. The timeline matters. Alzheimer’s disease typically develops gradually over years, while vascular dementia can progress in noticeable steps after strokes, and some rarer forms progress rapidly over months.
Family members or close friends play an important role here. People in the early stages of dementia often underestimate their own difficulties. Doctors sometimes use structured informant interviews, short questionnaires completed by someone who knows the patient well, to get an outside perspective. One widely used version, the AD8 screening interview, asks about eight specific changes in memory and thinking. A score of two or more out of eight suggests cognitive impairment worth investigating further.
Cognitive Screening Tests
Most doctors begin with a brief cognitive screening test that takes 10 to 30 minutes. The two most common are the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Both are scored out of 30 points, and both test orientation (knowing the date and where you are), memory recall, attention, language, and the ability to copy a simple drawing. The MoCA is generally considered more sensitive to early and subtle changes, particularly in areas like executive function, the higher-level thinking skills you use for planning and problem-solving.
These screening tests are useful starting points, but they’re blunt instruments. A low score doesn’t automatically mean dementia, and a normal score doesn’t rule it out. Education level, language barriers, anxiety, and even hearing loss can all skew results. When screening raises concerns, the next step is often a full neuropsychological evaluation.
Full Neuropsychological Testing
A neuropsychological evaluation is a far more detailed assessment, typically lasting several hours and administered by a neuropsychologist. It measures a broad range of mental functions: memory (both learning new information and recalling it later), processing speed, attention and concentration, reasoning and problem-solving, language comprehension and expression, executive functions like planning and multitasking, and visuospatial skills like understanding spatial relationships and copying complex figures.
The results are compared against norms for people of the same age and education level. This comparison is what makes the testing so valuable. It can reveal which specific cognitive areas are impaired, how severely, and whether the pattern of strengths and weaknesses matches a particular type of dementia. For example, Alzheimer’s disease tends to hit memory earliest and hardest, while frontotemporal dementia often shows up first as changes in personality, behavior, or language with memory relatively preserved.
Blood Tests to Rule Out Reversible Causes
Before attributing cognitive decline to a degenerative brain disease, doctors need to make sure something treatable isn’t causing the symptoms. Several conditions can mimic dementia, and some are fully reversible with treatment.
- Vitamin B12 deficiency can cause confusion, memory problems, and even personality changes that resolve once levels are restored.
- Thyroid dysfunction, particularly an underactive thyroid, can slow thinking and impair memory. Thyroid hormone and thyroid-stimulating hormone levels are standard parts of the workup.
- Kidney and liver problems can allow toxins to build up in the blood and affect brain function.
- Infections like HIV and syphilis are known to cause dementia-like symptoms and are tested when clinically appropriate.
- Blood sugar abnormalities and medication side effects, particularly from sedatives, antihistamines, and certain bladder medications, can also cloud cognition.
A complete blood count, metabolic panel, B12, thyroid levels, and sometimes a toxicology screen form the standard lab workup. If any of these come back abnormal, treating the underlying condition may improve or resolve the cognitive symptoms entirely.
The Neurological Exam
A physical neurological examination helps doctors differentiate between types of dementia by looking for telltale signs in the body, not just the mind. This involves testing reflexes, muscle tone, coordination, eye movements, and gait.
How someone walks can be surprisingly revealing. The shuffling, stooped gait with reduced arm swing typical of Parkinson’s disease looks very different from the wide-based, unsteady gait caused by damage to the brain’s coordination centers, or the “magnetic” gait of someone with frontal lobe disease whose feet seem stuck to the floor. A gait pattern that favors one side, with stiffness and exaggerated reflexes, can point to damage from a previous stroke.
Doctors also check for “primitive” reflexes, automatic responses that are normal in infants but re-emerge when the brain’s frontal lobes are damaged. These include the grasp reflex (involuntarily clasping when the palm is stroked) and the glabellar reflex (continued blinking when tapped between the eyebrows). The presence of multiple primitive reflexes increases the likelihood of a neurodegenerative disease, though no single reflex is specific to dementia.
Eye movements offer additional clues. A noticeable reduction in downward gaze can signal progressive supranuclear palsy, a rarer form of dementia. Tremor is another differentiator: it commonly accompanies Lewy body dementia but is not a feature of Alzheimer’s disease.
Brain Imaging
Most people undergoing a dementia workup will get at least one brain scan, typically an MRI. Imaging serves two purposes: ruling out structural problems like tumors, fluid buildup, or evidence of strokes, and identifying patterns of brain shrinkage that point toward a specific diagnosis.
In Alzheimer’s disease, the hippocampus, the brain’s primary memory center, is one of the first structures to shrink noticeably. Atrophy in the back of the brain involving the parietal and occipital regions also suggests Alzheimer’s pathology. Frontotemporal dementia, by contrast, shows disproportionate shrinkage in the frontal lobes or asymmetric wasting of the temporal lobes. Vascular dementia shows a different pattern entirely: areas of damage to the brain’s white matter, evidence of small vessel disease, or signs of previous strokes in critical brain regions.
For more specialized cases, doctors may order a PET scan. Amyloid PET scans use a radioactive tracer that binds to the amyloid plaques characteristic of Alzheimer’s disease, making them visible on imaging. In a large comparison study, amyloid PET scanning achieved 85% diagnostic accuracy for Alzheimer’s, with 88% sensitivity and 81% specificity. People with a positive amyloid PET scan were nearly four times more likely to progress from mild cognitive impairment to Alzheimer’s dementia than those with a negative scan.
Cerebrospinal Fluid Analysis
In some cases, particularly when the diagnosis is uncertain, doctors may recommend a lumbar puncture (spinal tap) to analyze cerebrospinal fluid. This fluid bathes the brain and spinal cord, and in Alzheimer’s disease it shows a characteristic pattern: lower-than-normal levels of amyloid-beta protein (because the protein is being trapped in plaques in the brain rather than flowing freely) and elevated levels of tau protein (released as brain cells are damaged).
While this test provides useful biological confirmation, it is more invasive than a blood draw and is not part of every diagnostic workup. It tends to be used when the clinical picture is ambiguous or when a definitive biological confirmation of Alzheimer’s would change treatment decisions.
Blood Tests for Alzheimer’s Biomarkers
One of the most significant recent advances in dementia diagnosis is the development of blood tests that can detect Alzheimer’s-related proteins. The most promising of these measures a specific form of the tau protein called p-tau217. In research studies, plasma p-tau217 tests have achieved 95% sensitivity and 94% specificity for identifying Alzheimer’s pathology, with an overall accuracy (AUC) of 0.98, which is exceptionally high for a blood-based test. It performs as well as cerebrospinal fluid analysis in many comparisons, without requiring a spinal tap.
These blood tests are not yet standard in most primary care settings. A commercial p-tau217 test currently costs around $194, but universal cutoff values for clinical use have not been fully established. The technology is advancing rapidly and is expected to transform early detection in the coming years, making it possible to identify Alzheimer’s disease before significant symptoms appear. For now, these tests are most commonly used in specialty clinics and research settings.
How the Pieces Come Together
No single test result drives the diagnosis. Instead, a clinician synthesizes everything: the patient’s history and reported symptoms, the informant’s observations, cognitive test scores, neurological exam findings, lab results, and imaging. The goal is to answer two questions. First, does this person meet the criteria for dementia, meaning significant cognitive decline that impairs daily independence? Second, what is the most likely cause?
The pattern of cognitive deficits, the physical exam findings, and the imaging results together point toward a specific type. Someone with progressive memory loss, hippocampal atrophy on MRI, and positive amyloid biomarkers has a strong case for Alzheimer’s disease. Someone with stepwise decline, vascular risk factors, and white matter disease on imaging fits a vascular dementia picture. Someone with early personality changes, loss of social awareness, and frontal lobe atrophy points toward frontotemporal dementia.
The full diagnostic process, from first concern to a specific diagnosis, can take anywhere from a few weeks to several months depending on how quickly testing can be scheduled and how straightforward the clinical picture is. In straightforward cases, a primary care physician may complete much of the workup. In complex or atypical presentations, referral to a neurologist, geriatrician, or memory clinic is common.